Effect of Acute Hepatic Failure on Epirubicin Pharmacokinetics after Intrahepatic Arterial Injection in Rats

One-Pot Synthesis of Epirubicin-Capped Silver Nanoparticles and Their Anticancer Activity against Hep G2 Cells

“…Epirubicin (Figure 1) is an anticancer prescription medicine for chemotherapy [17], which is proved to be effective to treat breast, lung, and liver cancers. It possesses several phenolic hydroxyl groups, thus exhibiting a weak reduction property.…”

Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats

“…We reported previously that the pharmacokinetics of epirubicin were affected in mild hepatic failure rats [17] . On the other hand, there was no significant difference in the plasma concentration of 5‐fluorouracil between rats with mild hepatic failure and their controls after both intravenous and intrahepatic arterial injection.…”

Comparison of blood dynamics of anticancer drugs (cisplatin, mitomycin C, epirubicin) in treatment groups of hepatic arterial infusion, hepatic arterial infusion with lipiodol and transcatheter arterial chemoembolization with lipiodol plus gelatin sponge particles in a swine model

“…Based on the serial data of plasma concentration, an approximate formula was estimated for the time–concentration curve, and the slope of the approximate formula was calculated. Outflow ratio was estimated based on area under the plasma concentration curve (AUC 0–60 ) 15 . AUC 0–60 was first calculated using the trapezoid rule, and outflow ratio was then calculated as follows: outflow ratio = AUC 0–60 / total infused dose of anticancer drug.…”